Cargando…
Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database
OBJECTIVE: To clarify the relationship among serum adiponectin, body composition, current disease activity and therapeutics of rheumatoid arthritis (RA). METHODS: We conducted a cross-sectional study in RA patients under treatment with agents including biological disease-modifying antirheumatic drug...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053773/ https://www.ncbi.nlm.nih.gov/pubmed/32126127 http://dx.doi.org/10.1371/journal.pone.0229998 |
_version_ | 1783503104810942464 |
---|---|
author | Minamino, Hiroto Katsushima, Masao Yoshida, Tamami Hashimoto, Motomu Fujita, Yoshihito Shirakashi, Mirei Yamamoto, Wataru Murakami, Kosaku Murata, Koichi Nishitani, Kohei Tanaka, Masao Ito, Hiromu Inagaki, Nobuya Matsuda, Shuichi |
author_facet | Minamino, Hiroto Katsushima, Masao Yoshida, Tamami Hashimoto, Motomu Fujita, Yoshihito Shirakashi, Mirei Yamamoto, Wataru Murakami, Kosaku Murata, Koichi Nishitani, Kohei Tanaka, Masao Ito, Hiromu Inagaki, Nobuya Matsuda, Shuichi |
author_sort | Minamino, Hiroto |
collection | PubMed |
description | OBJECTIVE: To clarify the relationship among serum adiponectin, body composition, current disease activity and therapeutics of rheumatoid arthritis (RA). METHODS: We conducted a cross-sectional study in RA patients under treatment with agents including biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase (JAK) inhibitors. A total of 351 subjects from the Kyoto University RA Management Alliance cohort (KURAMA) were enrolled in the analysis. We classified the participants into five body composition groups according to the cut-off points for obesity and visceral fat used in Japan: body mass index (BMI), 18.5 kg/m(2) for underweight and 25.0 kg/m(2) for obesity, and visceral fat area (VFA), 100 cm(2) for visceral adiposity. RESULTS: Classification of body composition revealed that serum adiponectin levels and disease activity score (DAS28-ESR) in the low BMI group were significantly higher than those in the normal and overweight groups. Because both increased serum adiponectin and low BMI were previously reported as poor prognostic factors of RA, we performed multiple regression analysis to determine which factor was correlated with RA disease activity. Serum adiponectin level, but not BMI, was positively associated with DAS28-ESR (estimate = 0.0127, p = 0.0258). Subanalysis also showed that the use of bDMARD or JAK inhibitor did not have an obvious influence on circulating adiponectin. CONCLUSIONS: Classification of body composition and multiple regression analysis revealed a positive and independent correlation between serum adiponectin and DAS28-ESR in Japanese RA patients. Thus, serum adiponectin may be an important marker reflecting high disease activity of RA regardless of current medications. |
format | Online Article Text |
id | pubmed-7053773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-70537732020-03-12 Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database Minamino, Hiroto Katsushima, Masao Yoshida, Tamami Hashimoto, Motomu Fujita, Yoshihito Shirakashi, Mirei Yamamoto, Wataru Murakami, Kosaku Murata, Koichi Nishitani, Kohei Tanaka, Masao Ito, Hiromu Inagaki, Nobuya Matsuda, Shuichi PLoS One Research Article OBJECTIVE: To clarify the relationship among serum adiponectin, body composition, current disease activity and therapeutics of rheumatoid arthritis (RA). METHODS: We conducted a cross-sectional study in RA patients under treatment with agents including biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase (JAK) inhibitors. A total of 351 subjects from the Kyoto University RA Management Alliance cohort (KURAMA) were enrolled in the analysis. We classified the participants into five body composition groups according to the cut-off points for obesity and visceral fat used in Japan: body mass index (BMI), 18.5 kg/m(2) for underweight and 25.0 kg/m(2) for obesity, and visceral fat area (VFA), 100 cm(2) for visceral adiposity. RESULTS: Classification of body composition revealed that serum adiponectin levels and disease activity score (DAS28-ESR) in the low BMI group were significantly higher than those in the normal and overweight groups. Because both increased serum adiponectin and low BMI were previously reported as poor prognostic factors of RA, we performed multiple regression analysis to determine which factor was correlated with RA disease activity. Serum adiponectin level, but not BMI, was positively associated with DAS28-ESR (estimate = 0.0127, p = 0.0258). Subanalysis also showed that the use of bDMARD or JAK inhibitor did not have an obvious influence on circulating adiponectin. CONCLUSIONS: Classification of body composition and multiple regression analysis revealed a positive and independent correlation between serum adiponectin and DAS28-ESR in Japanese RA patients. Thus, serum adiponectin may be an important marker reflecting high disease activity of RA regardless of current medications. Public Library of Science 2020-03-03 /pmc/articles/PMC7053773/ /pubmed/32126127 http://dx.doi.org/10.1371/journal.pone.0229998 Text en © 2020 Minamino et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Minamino, Hiroto Katsushima, Masao Yoshida, Tamami Hashimoto, Motomu Fujita, Yoshihito Shirakashi, Mirei Yamamoto, Wataru Murakami, Kosaku Murata, Koichi Nishitani, Kohei Tanaka, Masao Ito, Hiromu Inagaki, Nobuya Matsuda, Shuichi Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database |
title | Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database |
title_full | Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database |
title_fullStr | Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database |
title_full_unstemmed | Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database |
title_short | Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database |
title_sort | increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: a cross-sectional study using the kurama database |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053773/ https://www.ncbi.nlm.nih.gov/pubmed/32126127 http://dx.doi.org/10.1371/journal.pone.0229998 |
work_keys_str_mv | AT minaminohiroto increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT katsushimamasao increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT yoshidatamami increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT hashimotomotomu increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT fujitayoshihito increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT shirakashimirei increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT yamamotowataru increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT murakamikosaku increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT muratakoichi increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT nishitanikohei increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT tanakamasao increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT itohiromu increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT inagakinobuya increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase AT matsudashuichi increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase |